1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Analysis & Statistics in European Union, October 2019

Healthcare Analysis & Statistics in European Union, October 2019

1-30 of about 400 reports

Cyramza

Cyramza

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewCyramza (ramucirumab; Eli Lilly) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Nexavar

Nexavar

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewNexavar (sorafenib; Bayer/Amgen) is an orally available, multi-targeted tyrosine kinase inhibitor that is directed against several targets, including CRAF, BRAF, RET, KIT, FMS-like tyrosine ...

  • Industries : Pathology, Cancer, Therapy
  • Countries : United States, Japan, European Union
Tecentriq

Tecentriq

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewTecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union
Opdivo

Opdivo

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewOpdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Lenvima

Lenvima

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewLenvima (lenvatinib; Eisai/Merck and Co) is an orally available small molecule inhibitor of multiple tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR), platelet-derived ...

  • Industries : Pathology, Cancer
  • Countries : United States, Japan, European Union
Keytruda

Keytruda

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewKeytruda (pembrolizumab; Merck and Co) is a humanized monoclonal antibody designed to inhibit the PD-1 co-inhibitory receptor. The interaction between PD-1 and its primary ligand, PD-L1, inhibits ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Stivarga

Stivarga

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewStivarga (regorafenib; Bayer/Amgen) is an orally available small molecule inhibitor that is currently approved for the treatment of previously treated hepatocellular carcinoma patients. It ...

  • Industries : Pathology, Cancer
  • Countries : United States, Japan, European Union
Cabometyx

Cabometyx

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewCabometyx (cabozantinib; Exelixis/Ipsen/Takeda) is an orally available small molecule inhibitor which has been shown to suppress tumor growth and metastasis by inhibiting the activity of multiple ...

  • Industries : Pathology, Cancer
  • Countries : United States, Japan, European Union
Imfinzi

Imfinzi

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewImfinzi (durvalumab; AstraZeneca) is a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), ...

  • Industries : Pathology, Cancer
  • Countries : European Union, Japan, United States
Menveo

Menveo

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewMenveo (quadrivalent oligosaccharide diphtheria CRM-197 conjugate vaccine; GlaxoSmithKline) is a quadrivalent meningococcal glycoconjugate vaccine that uses CRM-197, a natural mutant of the ...

  • Industries : Therapy, Pathology
  • Countries : United States, European Union
Nimenrix

Nimenrix

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewNimenrix (quadrivalent polysaccharide tetanus toxoid conjugate vaccine; Pfizer) is a conjugated polysaccharide vaccine indicated for active immunization to prevent invasive meningococcal disease ...

  • Industries : Therapy, Pathology
  • Countries : European Union, Europe
Bexsero

Bexsero

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewBexsero (multicomponent meningococcal serogroup B vaccine; GlaxoSmithKline) is a multicomponent meningococcal serogroup B vaccine. It is approved for the prevention of invasive meningococcal ...

  • Industries : Therapy, Pathology, Medical Biotechnology, Pharmaceutical
  • Countries : United States, European Union
MenABCW-135Y

MenABCW-135Y

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewGlaxoSmithKline’s MenABCW-135Y is a pentavalent meningococcal conjugate vaccine for the A, B, C, W-135, and Y meningococcal strains. With all of the vaccine’s announced Phase II trials ...

  • Industries : Pathology, Therapy
  • Countries : United States, European Union
Elafibranor

Elafibranor

  • $ 10000
  • Industry report
  • July 2019

Elafibranor (Genfit) is an oral peroxisome proliferator-activated receptor (PPAR) alpha-delta dual agonist. The medication activates PPAR-alpha and PPAR-delta, which control gene expression. Stimulating ...

  • Industries : Healthcare
  • Countries : United States, European Union
Aramchol

Aramchol

  • $ 10000
  • Industry report
  • July 2019

Aramchol (arachidyl amido cholanoic acid; Galmed) is a conjugate of cholic acid and arachidic acid, and belongs to the synthetic fatty acid bile acid conjugates (FABACs) family. Aramchol inhibits the live ...

  • Industries : Healthcare
  • Countries : United States, European Union
Cenicriviroc

Cenicriviroc

  • $ 10000
  • Industry report
  • July 2019

Cenicriviroc (Allergan/Takeda) is a potent immunomodulator that blocks the chemokine receptors-2/5 (CCR-2/5). CCR-2/5 have been linked to the inflammatory and fibrogenic pathways in non-alcoholic steatohepatitis ...

  • Industries : Healthcare
  • Countries : United States, European Union
Juluca

Juluca

  • $ 10000
  • Industry report
  • June 2019

Juluca ([dolutegravir + rilpivirine]; ViiV Healthcare/Johnson and Johnson) is a single-tablet regimen approved in the US for the treatment of patients infected with HIV-1 who have achieved viral supp ...

  • Industries : Therapy
  • Countries : United States, European Union
Complera

Complera

  • $ 10000
  • Industry report
  • June 2019

Complera (rilpivirine/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Johnson and Johnson) is a single-tablet regimen for the treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Atripla

Atripla

  • $ 10000
  • Industry report
  • June 2019

Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Bristol-Myers Squibb) is a single-tablet regimen approved for the treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Genvoya

Genvoya

  • $ 10000
  • Industry report
  • June 2019

Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a single-tablet regimen (STR) approved for the treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Stribild

Stribild

  • $ 10000
  • Industry report
  • June 2019

Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Japan Tobacco) is a single-tablet regimen for the treatment of HIV-1 infection. It is a co-formulation of marketed ...

  • Industries : Therapy
  • Countries : United States, European Union, Japan
Tivicay

Tivicay

  • $ 10000
  • Industry report
  • June 2019

Tivicay (dolutegravir; ViiV Healthcare) is a once-daily, unboosted integrase inhibitor (INI) for the treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Isentress

Isentress

  • $ 10000
  • Industry report
  • June 2019

Isentress (raltegravir; Merck and Co) is a twice-daily, unboosted integrase inhibitor (INI) that is used in combination with other antiretroviral drugs for treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
leronlimab

leronlimab

  • $ 10000
  • Industry report
  • June 2019

Leronlimab (CytoDyn) is a humanized monoclonal antibody directed against C-C chemokine receptor 5 (CCR5), which is a co-receptor required for the attachment and entry of CCR5-tropic HIV-1 viruses into ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, European Union
Dovato

Dovato

  • $ 10000
  • Industry report
  • June 2019

Dovato ([dolutegravir + lamivudine]; ViiV Healthcare) is a single-tablet regimen approved in the US for the treatment of HIV-1 infection in patients who are treatment-naïve. It is also being developed ...

  • Industries : Therapy
  • Countries : United States, European Union
European Union (EU) Point-of-Care Ultrasound (PoCUS) Device Market

European Union (EU) Point-of-Care Ultrasound (PoCUS) Device Market

  • $ 3500
  • Industry report
  • May 2019

European Union (EU) Point-of-Care Ultrasound (PoCUS) Device MarketThe European Union point-of-care ultrasound (PoCUS) device market is predicted to attain a size of $230.9 million by 2024, advancing at ...

  • Industries : Health Services
  • Countries : European Union
Global Market for Arthroscopy Products and Sports Medicine Implants (2019)

Global Market for Arthroscopy Products and Sports Medicine Implants (2019)

  • $ 4750
  • Industry report
  • April 2019

This Meddevicetracker report provides an analysis of the market for arthroscopy products (including visualization systems, fluid management equipment, and manual and powered instruments) and sports medicine/soft ...

  • Industries : Diagnostic Imaging
  • Countries : World, United States, European Union
Cymbalta

Cymbalta

  • $ 10000
  • Industry report
  • March 2019

Eli Lilly’s Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor, was initially approved in the US in August 2004 for the treatment of major depressive disorder. The company has since ...

  • Industries : Pathology, Chronic Disease, Therapy, Mental Health
  • Countries : United States, Japan, European Union
Abilify/Abilify Maintena, Pharma Intelligence

Abilify/Abilify Maintena, Pharma Intelligence

  • $ 10000
  • Industry report
  • March 2019

Abilify (aripiprazole; Otsuka/Lundbeck) is an atypical antipsychotic that contains aripiprazole, a partial agonist of dopamine receptor D2 and serotonin receptor 5-HT1A, and antagonist of the 5-HT2A ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Seroquel/Seroquel XR, Pharma Intelligence

Seroquel/Seroquel XR, Pharma Intelligence

  • $ 10000
  • Industry report
  • March 2019

The Seroquel franchise contains quetiapine, which acts as an antagonist at multiple neurotransmitter receptors in the brain, such as serotonin 5-HT1A and 5-HT2, dopamine D1 and D2, histamine H1, and adrenergic ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
About 1300 reports

Download Unlimited Documents from Trusted Public Sources

Mining And Quarrying Industry in EU

  • October 2019
    4 pages
  • Sexually Transm...  

  • European Union  

    Europe  

View report >

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on